Linked Life Data

3123136

Source:http://linkedlifedata.com/resource/pubmed/id/3123136

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1988-2-26
pubmed:abstractText
The development of the antibodies to the combining site of an antigen-binding antibody has been documented in humans as well as experimental animals. These antibodies have been shown in experimental models to have an important regulatory role in their ability to affect both B- and T-cell responses to antigen. Recently, with the development of technology for cloning T cells, it has been possible to produce monoclonal antibodies to the T-cell receptor proteins. These T-cell antiidiotypic antibodies have been shown to activate both B- and T-cell responses. For this reason, such reagents have the potential to be used as nonantigen-containing immunogens. Our work has demonstrated that such monoclonal anti-T-cell antiidiotypes are capable of stimulating immunity to lethal viral infections. The implications of the use of antiidiotypes against infectious organisms are discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1040-8401
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
269-84
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
The use of antiidiotypic antibodies as vaccines against infectious agents.
pubmed:affiliation
Laboratory of Infectious Disease, Dana-Farber Cancer Institute, Boston, Massachusetts.
pubmed:publicationType
Journal Article, Review